Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Cleveland Clinic Mercy Hospital — Canton, Ohio
- Aultman Health Foundation — Canton, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Ohio: - University Hospitals Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- Oncology_Hematology Care Clinical Trials,LLC — Cincinnati, Ohio
- Oncology_Hematology Care Clinical Trials,LLC — Cincinnati, Ohio
- Oncology_Hematology Care Clinical Trials,LLC — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Ohio: - Aultman Hospital — Canton, Ohio
- Aultman Medical Group Hematology and Oncology — Canton, Ohio
- Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
- Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
- Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in Ohio: - University Hospitals Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- Gabrail Cancer Center Research — Canton, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- University Hospitals Seidman Cancer Center at UH Mentor Health Center — Mentor, Ohio
- UH Minoff Health Center at Chagrin Highlands — Orange, Ohio
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Ohio: - Research Site — Cincinnati, Ohio
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Ohio: - ProMedica Flower Hospital — Sylvania, Ohio
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Ohio: - Research Site — Cincinnati, Ohio
- Research Site — Columbus, Ohio
- Research Site — Maumee, Ohio
- Research Site — Toledo, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in Ohio: - Ohio State University — Columbus, Ohio
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …
Sponsor: Pfizer
NCT ID: NCT07226999
Sites in Ohio: - University Hospitals Cleveland Medical Center — Cleveland, Ohio
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Ohio: - Gabrail Cancer Center Research — Canton, Ohio
- The Christ Hospital Cancer Center — Cincinnati, Ohio
- University of Cincinnati Medical Center — Cincinnati, Ohio
- The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Ohio: - University of Cincinnati Medical Center ( Site 0119) — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Ohio: - Local Institution - 0383 — Cincinnati, Ohio
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
- Case Western (University Hospitals Case Medical Center) — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Ohio State University Wexner Medical Center — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Ohio: - Research Site — Canton, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in Ohio: - Cleveland Clinic - Akron General Medical Center — Akron, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Cleveland Clinic - Fairview Hospital Molly Pavilion — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Cleveland Clinic - Hillcrest Hospital Cancer Center — Mayfield Heights, Ohio
Phase 3 Recruiting Industry
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT07365241
Sites in Ohio: - Oncology Hematology Care - Fairfield /ID# 280641 — Fairfield, Ohio
Phase 3 Recruiting Industry
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Sponsor: Daiichi Sankyo
NCT ID: NCT06203210
Sites in Ohio: - Cleveland Clinic Mercy Hospital — Canton, Ohio
- Oncology/Hematology Care Clinical Trials, Llc — Cincinnati, Ohio
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Ohio: - University Hospitals Cleveland Medical Center — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C — Columbus, Ohio
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in Ohio: - University of Cincinnati Cancer Center — Cincinnati, Ohio
- The Ohio State University — Columbus, Ohio
Phase 3 Recruiting Industry
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Ohio: - University of Cincinnati Medical Center — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Ohio: - Aultman Health Foundation — Canton, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- ProMedica Flower Hospital — Sylvania, Ohio
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Ohio: - Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- Miami Valley Hospital — Dayton, Ohio
- Premier Blood and Cancer Center — Dayton, Ohio
- Miami Valley Hospital North — Dayton, Ohio
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio